The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …

Breast cancer remains a significant global health challenge, demanding innovative
therapeutic approaches. Polyphenols, a class of natural compounds widely distributed in …

Background Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive cancer that is
challenging to diagnose at an early stage. Despite recent advances in combination …

Simple Summary Nowadays, the upfront treatment for patients facing a diagnosis of
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …

CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are now standard first-line therapy for
advanced HR+/HER2− breast cancer, but developing resistance is just a matter of time in …

CDK4/6 inhibitors are routinely recommended agents for the treatment of advanced HR+
HER2− breast cancer. However, their therapeutic effectiveness in triple-negative breast …

Breast cancer is one of the most common malignant tumors with high mortality and poor
prognosis in women. There is an urgent need to discover new therapeutic targets for breast …

The cell cycle is the series of events that occur in a cell leading to its division and
duplication. It can be divided into two main stages: interphase and mitosis. Interphase is the …

Objectives To analyze the relationship between the clinical and pathological characters of
OSCC and COVID 19 exposure. Materials and Methods A retrospective cohort study in …

Background The combined use of CDK4/6 inhibitors and mTOR inhibitors has achieved
some clinical success in ccRCC. Exploring the underlying mechanism of the CDK4/6 …